Originally Posted by
Minerbarejet
1: Revenue excludes tests sold in the US for which cash payment has yet to be received, as well as tests completed for patients covered by the CMS. CMS tests account forapproximately 47% of annual US laboratory throughput and Pacific Edge will seek reimbursement for these when it is included in the CMS’s Local Coverage Determination (LCD). Asat 31 March 2019, Pacific Edge has completed and invoiced a total of 17,015 tests for CMS patients in the USA, for which we are yet to be reimbursed.
I make that nearly 20 million NZD. :)